Global expansion Leverage Macrilen across Europe and other non-U.S. markets where Aeterna Zentaris already has regulatory approvals or partnerships, targeting diagnostics adoption in endocrinology clinics and hospital networks.

Strategic partnerships Explore licensing or co-promotion deals in regions outside the U.S. with payors and distributors to accelerate adoption of macimorelin (Ghryvelin) for AGHD and CGHD diagnosis, capitalizing on existing Novo Nordisk royalty framework.

Portfolio monetization Monetize non-strategic assets and diagnostic/therapeutic assets through asset divestitures or collaborations, freeing capital for core macimorelin expansion and potential new diagnostic tests.

Clinical pipeline Sponsor or partner clinical studies for child-onset growth hormone deficiency and related endocrine indications to broaden the diagnostic and therapeutic value of macimorelin and attract payor coverage.

Digital reach Strengthen digital presence and demand generation using the current tech stack to improve outreach to endocrinologists, pediatrics, and hospital procurement teams, supporting faster lead conversion and market penetration.